Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2281-2285

  Koh, Won Jung ^a   Hong, Goohyeon ^a   Kim, Su Young ^a   Jeong, Byeong Ho ^a   Park, Hye Yun ^a   Jeon, Kyeongman ^a   Kwon, O Jung ^a   Lee, Seung Heon ^b   Kim, Chang Ki ^b   Shin, Sung Jae ^c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Korean Institute of Tuberculosis   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; ETHAMBUTOL; MOXIFLOXACIN; RIFAMPICIN; STREPTOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDICAL HISTORY; MYCOBACTERIUM AVIUM; PRIORITY JOURNAL; SPUTUM; SPUTUM CULTURE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; ETHAMBUTOL; FEMALE; HUMANS; LUNG; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; QUINOLINES; RIFAMPIN; SPUTUM;

EID: 84876249568     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02281-12     Document Type: Article

References (33)

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Jr, Winthrop K, ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Disease Society of America. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175:367-416.
2. Daley CL, Griffith DE. 2010. Pulmonary non-tuberculous mycobacterial infections. Int. J. Tuberc. Lung Dis. 14:665-671.
3. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, Montes de Oca R, Shea YR, Seitz AE, Holland SM, Olivier KN. 2010. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am. J. Respir. Crit. Care Med. 182: 970-976.
4. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. 2012. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am. J. Respir. Crit. Care Med. 185:881-886.
5. Moore JE, Kruijshaar ME, Ormerod LP, Drobniewski F, Abubakar I. 2010. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006. BMC Public Health 10:612. doi: 10.1186/1471-2458- 10-612.
6. Simons S, van Ingen J, Hsueh PR, Van Hung N, Dekhuijzen PN, Boeree MJ, van Soolingen D. 2011. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg. Infect. Dis. 17:343-349.
7. Field SK, Fisher D, Cowie RL. 2004. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 126:566-581.
8. Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, Daley CL, Catanzaro A. 2006. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 173:1283-1289.
9. Kobashi Y, Matsushima T, Oka M. 2007. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir. Med. 101:130-138.
10. Koh WJ, Jeong BH, Jeon K, Lee NY, Lee KS, Woo SY, Shin SJ, Kwon OJ. 2012. Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M. avium complex lung disease. Chest 142:1482-1488.
11. Gillespie SH, Billington O. 1999. Activity of moxifloxacin against mycobacteria. J. Antimicrob. Chemother. 44:393-395.
12. Bermudez LE, Inderlied CB, Kolonoski P, Petrofsky M, Aralar P, Wu M, Young LS. 2001. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Antimicrob. Agents Chemother. 45:217-222.
13. Sano C, Tatano Y, Shimizu T, Yamabe S, Sato K, Tomioka H. 2011. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium. Int. J. Antimicrob. Agents 37:296-301.
14. Griffith DE, Aksamit TR. 2012. Therapy of refractory nontuberculous mycobacterial lung disease. Curr. Opin. Infect. Dis. 25:218-227.
15. Sim YS, Park HY, Jeon K, Suh GY, Kwon OJ, Koh WJ. 2010. Standardized combination antibiotic treatment of Mycobacterium avium complex lung disease. Yonsei Med. J. 51:888-894.
16. Koh WJ, Jeong BH, Jeon K, Lee SY, Shin SJ. 2012. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 186:797-802.
17. Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, Nelson K, Caccitolo J, Alvarez J, Shepherd S, Wilson R, Graviss EA, Wallace RJ, Jr. 2006. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 174:928-934.
18. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard, 2nd ed. Document no. M24-A2. CLSI, Wayne, PA.
19. van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, Peloquin CA, Daley CL. 2012. The pharma cokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am. J. Respir. Crit. Care Med. 186:559-565.
20. Mickey RM, Greenland S. 1989. The impact of confounder selection criteria on effect estimation. Am. J. Epidemiol. 129:125-137.
21. Jacobson MA, Yajko D, Northfelt D, Charlebois E, Gary D, Brosgart C, Sanders CA, Hadley WK. 1993. Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection. J. Infect. Dis. 168:112-119.
22. Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. 2008. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 63:627-634.
23. Bermudez LE, Kolonoski P, Petrofsky M, Wu M, Inderlied CB, Young LS. 2003. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease. J. Infect. Dis. 187:1977-1980.
24. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. 1999. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 44:835-838.
25. Pranger AD, van Altena R, Aarnoutse RE, van Soolingen D, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW. 2011. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur. Respir. J. 38:888-894.
26. Kohno Y, Ohno H, Miyazaki Y, Higashiyama Y, Yanagihara K, Hirakata Y, Fukushima K, Kohno S. 2007. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Antimicrob. Agents Chemother. 51:4071-4076.
27. Kobashi Y, Yoshida K, Miyashita N, Niki Y, Oka M. 2006. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J. Infect. Chemother. 12:195-202.
28. Kobashi Y, Abe M, Mouri K, Obase Y, Kato S, Oka M. 2012. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. J. Infect. Chemother. 18:436-443.
29. Codecasa LR, Ferrara G, Ferrarese M, Morandi MA, Penati V, Lacchini C, Vaccarino P, Migliori GB. 2006. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir. Med. 100:1566-1572.
30. Lee J, Lee CH, Kim DK, Yoon HI, Kim JY, Lee SM, Yang SC, Lee JH, Yoo CG, Lee CT, Chung HS, Kim YW, Han SK, Yim JJ. 2011. Retrospective comparison of levofloxacin and moxifloxacin on multidrugresistant tuberculosis treatment outcomes. Korean J. Intern. Med. 26:153-159.
31. Koh WJ, Yu CM, Suh GY, Chung MP, Kim H, Kwon OJ, Lee NY, Chung MJ, Lee KS. 2006. Pulmonary TB and NTM lung disease: comparison of characteristics in patients with AFB smear-positive sputum. Int. J. Tuberc. Lung Dis. 10:1001-1007.
32. Kendall BA, Varley CD, Choi D, Cassidy PM, Hedberg K, Ware MA, Winthrop KL. 2011. Distinguishing tuberculosis from nontuberculous mycobacteria lung disease, Oregon, USA. Emerg. Infect. Dis. 17: 506-509.
33. Deshpande D, Srivastava S, Meek C, Leff R, Hall GS, Gumbo T. 2010. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. Antimicrob. Agents Chemother. 54: 2534-2539.